Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.50 -0.7%	$1.26	$0.86 ▼ $3.78	$330.28M	0.31	3.53 million shs	2.79 million shs
AVTE Aerovate Therapeutics	$8.33 -4.4%	$8.60	$56.35 ▼ $105.00	$241.45M	0.95	12,438 shs	130,060 shs
DBVT DBV Technologies	$9.57 -2.1%	$9.50	$2.20 ▼ $12.78	$267.73M	-0.59	18,906 shs	60,968 shs
GNTA Genenta Science	$3.81 0.0%	$3.89	$2.74 ▼ $7.28	$69.68M	0.59	26,367 shs	2,376 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-9.04%	+21.77%	+20.80%	-2.58%	-48.11%
AVTE Aerovate Therapeutics	-3.01%	-1.14%	-11.75%	-90.71%	-86.83%
DBVT DBV Technologies	+2.41%	+0.62%	+14.67%	+14.54%	+102.40%
GNTA Genenta Science	+1.86%	+0.90%	+24.19%	-5.32%	-12.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.2575 of 5 stars	4.5	1.0	0.0	0.0	2.8	2.5	0.6
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	3.9009 of 5 stars	4.4	5.0	0.0	0.0	1.9	2.5	0.6
GNTA Genenta Science	2.7337 of 5 stars	3.5	3.0	0.0	0.0	3.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	462.96% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	54.14% Upside
GNTA Genenta Science	3.00	Buy	$25.00	556.34% Upside

Current Analyst Ratings Breakdown

Latest GNTA, AVTE, DBVT, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	$2.01 per share	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
DBVT DBV Technologies	$4.15M	63.16	N/A	N/A	$1.42 per share	6.74
GNTA Genenta Science	N/A	N/A	N/A	N/A	$0.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
GNTA Genenta Science	-$9.64M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest GNTA, AVTE, DBVT, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AVTE Aerovate Therapeutics	-$0.25	N/A	N/A	N/A	N/A	N/A
8/6/2025	N/A	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
AVTE Aerovate Therapeutics	N/A	8.78	8.78
DBVT DBV Technologies	N/A	0.72	0.72
GNTA Genenta Science	N/A	6.89	6.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
AVTE Aerovate Therapeutics	N/A
DBVT DBV Technologies	71.74%
GNTA Genenta Science	15.13%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
AVTE Aerovate Therapeutics	24.90%
DBVT DBV Technologies	1.44%
GNTA Genenta Science	28.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable

GNTA, AVTE, DBVT, and ALLO Headlines

Recent News About These Companies

Genenta Science (NASDAQ:GNTA) Stock Price Down 1.3% - Here's Why

July 11, 2025 | marketbeat.com

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

July 1, 2025 | globenewswire.com

GNTA Genenta Science S.p.A.

May 30, 2025 | seekingalpha.com

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025 | newsfilecorp.comN

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

May 7, 2025 | globenewswire.com

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

April 15, 2025 | globenewswire.com

Genenta Science announces EUR 20M financing to expand pipeline

March 21, 2025 | markets.businessinsider.com

Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research

March 19, 2025 | tipranks.com

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

March 19, 2025 | globenewswire.com

Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?

February 13, 2025 | msn.com

Genenta Science SpA ADR

February 1, 2025 | investing.com

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

January 28, 2025 | prnewswire.com

Genenta Science announces amendment to pact with AGC Biologics

January 10, 2025 | finance.yahoo.com

Genenta, AGC Biologics Strengthen Cell Therapy Manufacturing Pact

January 9, 2025 | contractpharma.comC

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

January 9, 2025 | globenewswire.com

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

January 8, 2025 | prnewswire.com

Genenta Science Enhances Manufacturing Agreement with AGC Biologics

January 1, 2025 | markets.businessinsider.com

Genenta Science Updates ATM Sales Agreement with New Agent

December 20, 2024 | tipranks.com

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

October 23, 2024 | globenewswire.com

Genenta Science (NASDAQ:GNTA) Stock Quotes, Forecast and News Summary

October 11, 2024 | benzinga.com

Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders

October 11, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA, AVTE, DBVT, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.50 -0.01 (-0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.00 (+0.33%)

As of 07:55 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Aerovate Therapeutics NASDAQ:AVTE

$8.33 -0.38 (-4.36%)

As of 07/24/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.57 -0.20 (-2.06%)

Closing price 03:59 PM Eastern

Extended Trading

$9.57 +0.00 (+0.02%)

As of 05:08 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Genenta Science NASDAQ:GNTA

$3.82 +0.00 (+0.13%)

As of 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time